Table 3

Treatment-emergent adverse events*

Semaglutide 1.0 mgExenatide ER 2.0 mg
Subjects experiencing ≥1 event, n (%) (n = 404)Events, nEvent rateSubjects experiencing ≥1 event, n (%) (n = 405)Events, nEvent rate
AEs303 (75.0)1,551374.7309 (76.3)1,511370.4
Serious AEs38 (9.4)5212.624 (5.9)276.6
AEs leading to treatment discontinuation38 (9.4)4811.629 (7.2)4711.5
AEs occurring in ≥5% of subjects
 Nausea90 (22.3)15938.448 (11.9)7017.2
 Diarrhea46 (11.4)8620.834 (8.4)5814.2
 Lipase increased41 (10.1)5112.349 (12.1)6415.7
 Nasopharyngitis39 (9.7)4611.138 (9.4)5112.5
 Headache38 (9.4)8119.639 (9.6)6515.9
 Decreased appetite32 (7.9)348.221 (5.2)245.9
 Vomiting29 (7.2)378.925 (6.2)409.8
 Dyspepsia27 (6.7)338.019 (4.7)235.6
 Constipation26 (6.4)286.821 (5.2)266.4
 Injection-site nodule0 (0.0)0049 (12.1)5513.5
  • *Treatment-emergent AE (by preferred term) include events with onset at or after the date of the first trial product dose and before or at the date of the last trial medication dose plus 5 weeks plus the 7-day visit window for the end-of-treatment follow-up visit (42 days).

  • †Event rate per 100 years of treatment exposure.